Experienced in Ecthyma

Jean-luc L. Perrot

Saint-priest-la-vetre, FR 
Experienced in Ecthyma
Saint-priest-la-vetre, FR 
OverviewLocationsClinical Research

Overview

Jean-luc Perrot practices in Saint-priest-la-vetre, France. Mr. Perrot is rated as an Experienced expert by MediFind in the treatment of Ecthyma. His top areas of expertise are Basal Cell Skin Cancer, Melanoma, Pigmented Purpuric Dermatosis, and Seborrheic Keratosis.

His clinical research consists of co-authoring 170 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Ecthyma.

Gender
Male

Locations

Saint-priest-la-vetre, France
Other Locations
Saint-etienne-de-valoux, France
Saint-etienne, France
Paris, France
Polyclinique Courlancy
Reims, France
Ecully, France
Lille, France
Ecole, France
Saint Étienne, France
Ville-sur-yron, France
St Priest En Jarez, Sete, 42270, France
Saint-jean-saint-germain, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
In Vivo Imaging Innovation : Optical Coherence Microscopy in Dermato-oncology
In Vivo Imaging Innovation : Optical Coherence Microscopy in Dermato-oncology
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Device
Study Phase: Not Applicable
In Vivo Imaging Innovation : Optical Coherence Microscopy in Dermato-oncology
In Vivo Imaging Innovation : Optical Coherence Microscopy in Dermato-oncology
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Device
Study Phase: Not Applicable
View 2 Less Clinical Trials

170 Total Publications

Multimodal imaging of cutaneous solitary plasmacytoma: Line-field confocal optical coherence tomography, in vivo and ex vivo confocal microscopy.
Multimodal imaging of cutaneous solitary plasmacytoma: Line-field confocal optical coherence tomography, in vivo and ex vivo confocal microscopy.
Journal: JAAD case reports
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Perrot's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 36 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile